Cargando…

Pulmonary Hypertension Caused by Interstitial Lung Disease: A New iNK(T)ling into Disease Pathobiology

Detalles Bibliográficos
Autores principales:	Hersi, Kadija, Elinoff, Jason M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2022
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801987/ https://www.ncbi.nlm.nih.gov/pubmed/35772120 http://dx.doi.org/10.1164/rccm.202206-1186ED

Ejemplares similares

Nitric oxide deficiency in pulmonary hypertension: Pathobiology and implications for therapy
por: Tonelli, Adriano R., et al.
Publicado: (2013)

Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives
por: Humbert, Marc, et al.
Publicado: (2019)

Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled
por: Hemnes, Anna R., et al.
Publicado: (2017)

Depression in Pulmonary Arterial Hypertension and Interstitial Lung Diseases
por: Verma, Sameer, et al.
Publicado: (2014)

Noninvasive determinants of pulmonary hypertension in interstitial lung disease
por: Joseph, Phillip, et al.
Publicado: (2023)

Pulmonary Artery Size in Interstitial Lung Disease and Pulmonary Hypertension: Association with Interstitial Lung Disease Severity and Diagnostic Utility
por: Chin, Matthew, et al.
Publicado: (2018)

Ling-Ling Chen: Shaping a career in RNA biology
por: O’Donnell, Marie Anne
Publicado: (2017)

Pathobiology of Alzheimer's disease /
Publicado: (1995)

Pulmonary Hypertension in Interstitial Lung Disease: Updates in Disease, Diagnosis, and Therapeutics
por: Haynes, Zachary A., et al.
Publicado: (2023)

Pulmonary arterial hypertension in systemic sclerosis—when criteria and pathobiology differ
por: Andréasson, Kristofer, et al.
Publicado: (2019)

Recent advances in the management of pulmonary hypertension with interstitial lung disease
por: Waxman, Aaron B., et al.
Publicado: (2022)

Imaging Biomarkers and Pathobiological Profiling in a Rat Model of Drug-Induced Interstitial Lung Disease Induced by Bleomycin
por: Mahmutovic Persson, Irma, et al.
Publicado: (2020)

Pathobiology of Paget's Disease of Bone
por: Galson, Deborah L., et al.
Publicado: (2014)

Inhibitory Potential of Shen-Shuai-Ling Formulation on Renal Interstitial Fibrosis via Upregulation of PLZF
por: Song, Na, et al.
Publicado: (2022)

Predictors of mortality in interstitial lung disease patients without pulmonary hypertension
por: Alhamad, Esam H., et al.
Publicado: (2020)

Predictors of Mortality in Patients with Interstitial Lung Disease-Associated Pulmonary Hypertension
por: Alhamad, Esam H., et al.
Publicado: (2020)

Pulmonary hypertension in interstitial lung disease: an area of unmet clinical need
por: Dhont, Sebastiaan, et al.
Publicado: (2022)

Angiogenic factors, bladder neuroplasticity and interstitial cystitis—new pathobiological insights
por: Saban, Ricardo
Publicado: (2015)

Advanced interstitial lung fibrosis with emphysema and pulmonary hypertension with no evidence for interstitial lung disease on high resolution CT
por: Foris, Vasile, et al.
Publicado: (2019)

Shen-Shuai-Ling Formulation Attenuates Renal Interstitial Fibrosis in Chronic Kidney Disease by Regulating SHH-Gli1 Signaling Pathway
por: Li, Ying, et al.
Publicado: (2022)

Commentary: Imaging Biomarkers and Pathobiological Profiling in a Rat Model of Drug-Induced Interstitial Lung Disease (DIILD) Induced by Bleomycin
por: Sinis, Sotirios I., et al.
Publicado: (2021)

Professor Ya-Ling Han
por: Zhang, He, et al.
Publicado: (2013)

First person – Ling Wang
Publicado: (2019)

Immune repertoire profiling for disease pathobiology
por: Katoh, Hiroto, et al.
Publicado: (2022)

Interstitial lung disease and pre-capillary pulmonary hypertension in neurofibromatosis type 1
por: Rodrigues, Daniela, et al.
Publicado: (2018)

Clinical Retrospective Analysis of Interstitial Lung Disease Patients Associated with Pulmonary Hypertension
por: Lv, Hongxia, et al.
Publicado: (2019)

Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension
por: Guillén-Del-Castillo, Alfredo, et al.
Publicado: (2022)

Pulmonary hypertension in patients with interstitial lung disease: a tool for early detection
por: Parikh, Raj, et al.
Publicado: (2022)

Response to letter to the editor “noninvasive determinants of pulmonary hypertension in interstitial lung disease”
por: Joseph, Phillip, et al.
Publicado: (2023)

The Role of Mitochondria and Oxidative/Antioxidative Imbalance in Pathobiology of Chronic Obstructive Pulmonary Disease
por: Białas, Adam Jerzy, et al.
Publicado: (2016)

Pathobiology
Publicado: (2015)

Pathobiology
Publicado: (2015)

Telomere Abnormalities in the Pathobiology of Idiopathic Pulmonary Fibrosis
por: Bilgili, Hasancan, et al.
Publicado: (2019)

Pulmonary hypertension due to unclassified interstitial lung disease in a Pembroke Welsh corgi
por: MORITA, Tomoya, et al.
Publicado: (2018)

Inhaled Treprostinil in Pulmonary Hypertension in the Context of Interstitial Lung Disease: A Success, Finally
por: Behr, Jürgen
Publicado: (2021)

The Challenge of Diagnosing and Managing Pulmonary Arterial Hypertension in Systemic Sclerosis with Interstitial Lung Disease
por: Zanatta, Elisabetta, et al.
Publicado: (2022)

Pulmonary Hypertension in Interstitial Lung Disease: Management Options to Move Beyond Supportive Care
por: Fabyan, Kimberly D., et al.
Publicado: (2023)

First person – Ling-shiang Chuang
Publicado: (2019)

Protein glycosylation in infectious disease pathobiology and treatment
por: Vigerust, David J.
Publicado: (2011)

Uncovering common pathobiological processes between COVID‐19 and pulmonary arterial hypertension by integrating Omics data
por: Wang, Rui‐Sheng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jta5fihnjioqc7fk44idhgb24q